(RTTNews) - Wednesday, Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for Koselugo for the ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic ...

Alexion Pharmaceuticals (NASDAQ: ALXN) is a US-headquartered biopharmaceutical company focused on developing and delivering therapies for patients with severe and life-threatening diseases. Alexion ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

SINGAPORE: Singapore and South Korea launched a logo to be used in events celebrating the 50th anniversary of diplomatic relations between the two countries. The logo, unveiled on Monday (Jan 13 ...

Alexion has gained FDA approval for Kanuma, its treatment for the rare disease lysosomal acid lipase (LAL) deficiency. Alexion says Kanuma (sebelipase alfa) could eventually bring in more than $ ...

Seasoned advisory group including RNA, translation and commercialisation luminaries.

Eculizumab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome. According to ...

Efzimfotase alfa is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Hypophosphatasia. According to GlobalData, Phase III drugs for Hypophosphatasia have a 100% ...